Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer

John K. Chan, Vera Loizzi, Alessandra Magistris, Fritz Lin, Joanne Rutgers, Kathryn Osann, Philip J. DiSaia, Michael L. Berman

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to determine whether differences in molecular markers might explain the better prognosis of women ≤45 years of age versus women >45 years of age diagnosed with ovarian cancers. Experimental Design: Tissue sections from women with stage III-IV ovarian cancers were examined for expression of CD34, p53, and HER2. The Kaplan-Meier method and Cox Proportional Hazard analyses were used to identify predictors for outcome. Results: Fifty-two women ≤45 years of age were matched with 52 women who were >45 years old. Of the 46 available tissue sections, 24 were from the younger age group (mean age, 41 years), and 22 were from the older age group (mean age, 61 years). Based on CD34 expression, tumors from women >45 years of age had lower microvessel density (MVD) compared with tumors of younger women (10.3 versus 16.1 microvessels per ×400 field; P = 0.03). Lower MVD (≤11 microvessels per ×400 field) predicted for a worse prognosis than higher MVD (>11 microvessels per ×400 field) in the overall study group (P = 0.001) and within the older subgroup (P = 0.03). The expressions of p53 (P = 0.13) and HER2 (P = 0.49) did not vary between the two age groups. The median survivals of those with tumors that overexpressed p53 and HER2 were 28.6 and 23.9 months compared with 51.7 and 38.6 months in those with cancers that underexpressed these markers, respectively (P = 0.09 for p53, P = 0.15 for HER2). Conclusions: Ovarian cancers in women >45 years of age had lower MVD compared with those in women ≤45 years of age. Lower MVD was an independent prognostic factor for decreased survival. Lower frequency of neovascularization in these cancers may contribute to the decreased survival observed in women >45 years of age.

Original languageEnglish
Pages (from-to)8538-8543
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number24
DOIs
Publication statusPublished - Dec 15 2004

Fingerprint

Ovarian Neoplasms
Microvessels
Age Groups
Neoplasms
Survival
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer. / Chan, John K.; Loizzi, Vera; Magistris, Alessandra; Lin, Fritz; Rutgers, Joanne; Osann, Kathryn; DiSaia, Philip J.; Berman, Michael L.

In: Clinical Cancer Research, Vol. 10, No. 24, 15.12.2004, p. 8538-8543.

Research output: Contribution to journalArticle

Chan, John K. ; Loizzi, Vera ; Magistris, Alessandra ; Lin, Fritz ; Rutgers, Joanne ; Osann, Kathryn ; DiSaia, Philip J. ; Berman, Michael L. / Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 24. pp. 8538-8543.
@article{96c2f4af771943818a3469ba4d06537f,
title = "Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer",
abstract = "Purpose: The purpose of this study was to determine whether differences in molecular markers might explain the better prognosis of women ≤45 years of age versus women >45 years of age diagnosed with ovarian cancers. Experimental Design: Tissue sections from women with stage III-IV ovarian cancers were examined for expression of CD34, p53, and HER2. The Kaplan-Meier method and Cox Proportional Hazard analyses were used to identify predictors for outcome. Results: Fifty-two women ≤45 years of age were matched with 52 women who were >45 years old. Of the 46 available tissue sections, 24 were from the younger age group (mean age, 41 years), and 22 were from the older age group (mean age, 61 years). Based on CD34 expression, tumors from women >45 years of age had lower microvessel density (MVD) compared with tumors of younger women (10.3 versus 16.1 microvessels per ×400 field; P = 0.03). Lower MVD (≤11 microvessels per ×400 field) predicted for a worse prognosis than higher MVD (>11 microvessels per ×400 field) in the overall study group (P = 0.001) and within the older subgroup (P = 0.03). The expressions of p53 (P = 0.13) and HER2 (P = 0.49) did not vary between the two age groups. The median survivals of those with tumors that overexpressed p53 and HER2 were 28.6 and 23.9 months compared with 51.7 and 38.6 months in those with cancers that underexpressed these markers, respectively (P = 0.09 for p53, P = 0.15 for HER2). Conclusions: Ovarian cancers in women >45 years of age had lower MVD compared with those in women ≤45 years of age. Lower MVD was an independent prognostic factor for decreased survival. Lower frequency of neovascularization in these cancers may contribute to the decreased survival observed in women >45 years of age.",
author = "Chan, {John K.} and Vera Loizzi and Alessandra Magistris and Fritz Lin and Joanne Rutgers and Kathryn Osann and DiSaia, {Philip J.} and Berman, {Michael L.}",
year = "2004",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-04-0626",
language = "English",
volume = "10",
pages = "8538--8543",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer

AU - Chan, John K.

AU - Loizzi, Vera

AU - Magistris, Alessandra

AU - Lin, Fritz

AU - Rutgers, Joanne

AU - Osann, Kathryn

AU - DiSaia, Philip J.

AU - Berman, Michael L.

PY - 2004/12/15

Y1 - 2004/12/15

N2 - Purpose: The purpose of this study was to determine whether differences in molecular markers might explain the better prognosis of women ≤45 years of age versus women >45 years of age diagnosed with ovarian cancers. Experimental Design: Tissue sections from women with stage III-IV ovarian cancers were examined for expression of CD34, p53, and HER2. The Kaplan-Meier method and Cox Proportional Hazard analyses were used to identify predictors for outcome. Results: Fifty-two women ≤45 years of age were matched with 52 women who were >45 years old. Of the 46 available tissue sections, 24 were from the younger age group (mean age, 41 years), and 22 were from the older age group (mean age, 61 years). Based on CD34 expression, tumors from women >45 years of age had lower microvessel density (MVD) compared with tumors of younger women (10.3 versus 16.1 microvessels per ×400 field; P = 0.03). Lower MVD (≤11 microvessels per ×400 field) predicted for a worse prognosis than higher MVD (>11 microvessels per ×400 field) in the overall study group (P = 0.001) and within the older subgroup (P = 0.03). The expressions of p53 (P = 0.13) and HER2 (P = 0.49) did not vary between the two age groups. The median survivals of those with tumors that overexpressed p53 and HER2 were 28.6 and 23.9 months compared with 51.7 and 38.6 months in those with cancers that underexpressed these markers, respectively (P = 0.09 for p53, P = 0.15 for HER2). Conclusions: Ovarian cancers in women >45 years of age had lower MVD compared with those in women ≤45 years of age. Lower MVD was an independent prognostic factor for decreased survival. Lower frequency of neovascularization in these cancers may contribute to the decreased survival observed in women >45 years of age.

AB - Purpose: The purpose of this study was to determine whether differences in molecular markers might explain the better prognosis of women ≤45 years of age versus women >45 years of age diagnosed with ovarian cancers. Experimental Design: Tissue sections from women with stage III-IV ovarian cancers were examined for expression of CD34, p53, and HER2. The Kaplan-Meier method and Cox Proportional Hazard analyses were used to identify predictors for outcome. Results: Fifty-two women ≤45 years of age were matched with 52 women who were >45 years old. Of the 46 available tissue sections, 24 were from the younger age group (mean age, 41 years), and 22 were from the older age group (mean age, 61 years). Based on CD34 expression, tumors from women >45 years of age had lower microvessel density (MVD) compared with tumors of younger women (10.3 versus 16.1 microvessels per ×400 field; P = 0.03). Lower MVD (≤11 microvessels per ×400 field) predicted for a worse prognosis than higher MVD (>11 microvessels per ×400 field) in the overall study group (P = 0.001) and within the older subgroup (P = 0.03). The expressions of p53 (P = 0.13) and HER2 (P = 0.49) did not vary between the two age groups. The median survivals of those with tumors that overexpressed p53 and HER2 were 28.6 and 23.9 months compared with 51.7 and 38.6 months in those with cancers that underexpressed these markers, respectively (P = 0.09 for p53, P = 0.15 for HER2). Conclusions: Ovarian cancers in women >45 years of age had lower MVD compared with those in women ≤45 years of age. Lower MVD was an independent prognostic factor for decreased survival. Lower frequency of neovascularization in these cancers may contribute to the decreased survival observed in women >45 years of age.

UR - http://www.scopus.com/inward/record.url?scp=11144224484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144224484&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0626

DO - 10.1158/1078-0432.CCR-04-0626

M3 - Article

C2 - 15623636

AN - SCOPUS:11144224484

VL - 10

SP - 8538

EP - 8543

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -